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Background:  There are many studies regarding the effects of insulin on bone metabolism and changes in bone mineral density 
(BMD) in the setting of diabetes. The effect of prediabetes on BMD is not known.
Methods:  A total of 802 men participated in the Korea Rural Genomic Cohort Study (in Geumsan County). According to the 
results of an oral glucose tolerance test, subjects were classified into normal, prediabetic, and diabetic categories. One hundred 
twenty-four subjects diagnosed with type 2 diabetes were excluded, leaving 678 subjects for the study inclusion. BMD was esti-
mated with a quantitative ultrasonometer. 
Results:  The average BMD T scores of normal and prediabetic subjects were -1.34 ± 1.42 and -1.33 ± 1.30, respectively; there 
was no significant difference in the BMD T scores between these groups. The BMD T score was inversely associated with age and 
positively correlated with body weight, body mass index, total cholesterol, low density lipoprotein cholesterol, and HbA1c. On 
multiple linear regression analysis, low density lipoprotein cholesterol was the only statistically significant variable for prediabetes 
(β = 0.007, P = 0.005). On the stepwise regression analysis, age (β = -0.026, P < 0.001), the body mass index (β = 0.079, P < 0.001), 
and low density lipoprotein cholesterol (β = 0.004, P = 0.016) were significant variables for prediabetes.
Conclusions:  There was no significant difference in the BMD T score between the normal and prediabetic subjects. Further stud-
ies are needed regarding the association of fracture risk and changes in BMD with the development of overt diabetes.
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INTRODUCTION
The incidence of diabetes in Korea is on the rise. According to 
the Korean National Health and Nutrition Examination Survey 
(KNHNES) in 2007, the rate of diabetes reached 9.7% in adults 
older than 30 years; impaired fasting glucose reached 16.1%. 
Additionally, osteoporosis, and consequent fractures, are on 
the rise. In the KNHNES in 2008, the incidence of osteoporo-
sis in postmenopausal women and males older than 50 years 
has been reported to be high as 19.3% [1]. Osteoporosis refers 
to the reduction of bone strength and causes an increased risk 
of fracture. The World Health Organization (WHO) defines 
osteoporosis as a bone mineral density (BMD) that falls 2.5 
standard deviations below the mean for young healthy adults 
of the same gender, also referred to as a T-score of -2.5 [2]. 
  Several studies have reported on the effects of insulin and 
diabetes on bone metabolism. A meta-analysis of the studies 
found that BMD was decreased in type 1 diabetes, but that type 
2 diabetes either did not significantly affect the BMD or was 
associated with a slightly increased BMD [3]. The mechanisms 
for these findings have not yet been elucidated. It is thought 
that insulin mediates anabolic effects on bone metabolism and 
that insulin may exert synergistic effects together with other 
anabolic agents, such as insulin-like growth factor (IGF)-I and 
parathyroid hormone [4]. Therefore, bone metabolism may be 
altered in patients with impaired fasting glucose (IFG) or im-
paired glucose tolerance (IGT). However, studies of bone me-
tabolism in prediabetic patients have not yet been conducted. 
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Therefore, the current study examined the changes in BMD in 
patients with IFG or IGT. 
 
METHODS
Participants
Among the 1,993 individuals who participated in the Korean 
Rural Genome Cohort Study from January 2005 to December 
2006, 802 males were selected as the study subjects. Among 
these, we excluded 124 subjects who were diagnosed as diabetic. 
The Korean Rural Genome Cohort Study was conducted on 
individuals between the ages of 40 to 70 years and who resided 
in Wonju-si, Pyeongchang-gun, and Gangneung-si in Gang-
won-do, Geumsan-gun in Chungcheong-do, and Naju-si in 
Jeolla-do. The subjects of this study were recruited randomly 
from Geumsan-gun.
  Based on the definition of the American Diabetes Associa-
tion in 2004, subjects with either an IFG or an IGT were classi-
fied as prediabetic. Cases with fasting blood glucose between 
100 mg/dL and 126 mg/dL were diagnosed as IFG. Cases with 
blood glucose was between 140 mg/dL and 200 mg/dL at 2 hours 
after a 75 g oral glucose loading were diagnosed as IGT [5]. 
Methods
Physical measurements 
Height and weight were measured by a single individual. The 
waist and hip circumference were measured with the subject 
standing straight. For obtaining the waist circumference, ac-
cording to the method recommended by the WHO, the patients 
stood with legs 25–30 cm apart and, while distributing weight 
evenly, the middle area between the lowest rib and the pelvic 
iliac crest was measured during the end-expiration phase. The 
body mass index (BMI) was calculated by the formula: weight 
(kg)/height (m
2).
 
Body fat measurement
The fat mass (kg), percent body fat (%), visceral fat (kg), and 
percent visceral fat (%) were measured by a body composition 
analyzer (InBody 4.0; Biospace Co., Seoul, Korea).
Evaluation of glucose metabolism
For all subjects, the glycosylated hemoglobin was measured 
and the blood glucose, as well as insulin, were measured after 
fasting (minimum 12 hours) and 120 minutes after the oral 
administration of 75 g of glucose. Insulin was measured by a 
radioimmune assay (Biosource, Fleurus, Belgium). The intra-
assay coefficient of variation was 2.41% and the inter-assay co-
efficient of variation was 2.93%. 
Blood chemistries
In all subject groups, after fasting for more than 12 hours, the 
blood urea nitrogen, serum creatine, serum cholesterol, triglyc-
eride, low density lipoprotein cholesterol (LDL-C), high den-
sity lipoprotein cholesterol, aspartate aminotransferase, and 
alanine transaminase were measured. 
BMD
In all subjects, the BMD was measured in the calcaneus using 
an ultrasonographic bone densitometer (ACHILLES Express; 
GE, Madison, WI, USA). Additionally, the T-score was divided 
into three groups according to the classification of the WHO as 
normal when greater than -1.0, osteopenia when it was between 
-2.5 and -1.0, and osteoporosis when it was less than -2.5. 
Statistical analysis
All statistical procedures were carried out with SPSS for win-
dows version 17.0 (SPSS Inc., Chicago, IL, USA). All values are 
presented as the mean ± standard deviation. Student’s t-test and 
the chi-square test were performed to compare the clinical 
characteristic of the two groups classified as the normal and 
prediabetic group. One-way ANOVA was applied for compar-
ative analysis of the BMD. The Pearson’s correlation method 
was applied for analysis of the correlation of BMD with the 
various clinical characteristics. To determine the factors hav-
ing the greatest effects on BMD, multiple regression analysis 
was performed and confirmed by correlation analysis; P values 
less than 0.05 were considered statistically significant.
RESULTS
Comparison of clinical characteristics and BMD 
Among the 678 study patients, 406 were classified as normal 
and 272 were classified as prediabetic. Compared with the 
normal group, the prediabetic group had significantly higher 
values for fasting blood glucose concentration and blood glu-
cose concentration 2 hours after a 75 g oral glucose load, serum 
insulin concentration 2 hours after a 75 g oral glucose load, 
and glycosylated hemoglobin (100.78 ± 11.03 mg/dL vs. 89.49 
± 6.47 mg/dL, 147.22 ± 31.17 mg/dL vs. 102.12 ± 23.74 mg/dL, 
32.71 ± 27.28 mU/L vs. 23.91 ± 22.28 mU/L, and 5.57 ± 0.45 296
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mg/dL vs. 5.41 ± 0.36 mg/dL, respectively, P < 0.001). However, 
the fasting serum insulin concentration was not significantly 
different between these groups (7.63 ± 3.60 mU/L vs. 7.31 ± 
4.05 mU/L, respectively, P = 0.295). There was no significant 
difference in age, BMI, percent body fat, and waist circumfer-
ence between the two groups. The mean BMD T-score of the 
Table 1.  Characteristics according to normal and prediabetic status
           Group
P value
Normal (n = 406)  IFG or IGT (n = 272) 
Age, yr 56.55 ± 7.36 57.49 ± 7.18 0.105
a
Hypertension
Negative 331 (81.5) 206 (75.7) 0.069
b
Positive 75 (18.5) 66 (24.3)
Dyslipidemia
Negative 387 (95.3) 254 (93.4) 0.276
b
Positive 19 (4.7) 18 (6.6)
T score group
≥ -1.0 160 (40.2) 106 (38.5) 0.688
b
-1.0 >  ≥ -2.5 168 (42.2) 125 (45.5)
< -2.5 70 (17.6) 44 (16.0)
BMD T score  -1.34 ± 1.42 -1.33 ± 1.30 0.924
a 
HbA1C, % 5.41 ± 0.36 5.57 ± 0.45 < 0.001
a 
Fasting insulin, mU/L 7.31 ± 4.05 7.63 ± 3.60 0.295
a 
Fasting glucose, mg/dL 89.49 ± 6.47 100.78 ± 11.03 < 0.001
a
2 hr-insulin, mU/L 23.91 ± 22.28 32.71 ± 27.28 < 0.001
a
2 hr- glucose, mg/dL 102.12 ± 23.74 147.22 ± 31.17 < 0.001
a
Height, cm 166.26 ± 6.05 165.49 ± 5.97 0.102
a
Weight, kg 64.72 ± 9.75 65.10 ± 9.51 0.619
a
Body mass index, kg/m
2 23.38 ± 3.02 23.72 ± 2.91 0.140
a
Waist circumference, cm 87.02 ± 8.84 87.95 ± 8.45 0.171
a
Percent body fat, % 21.5 ± 5.13 22.25 ± 4.79 0.715
a
Visecral fat, kg 2.15 ± 1.30 2.18 ± 0.87 0.740
a
Percent visceral fat, % 11.44 ± 2.38 11.73 ± 2.06 0.089
a
Total cholesterol, mg/dL 204.57 ± 37.24 203.82 ± 38.10 0.797
a
Triglyceride, mg/dL 169.93 ± 117.99 186.12 ± 116.53 0.079
a
HDL-C, mg/dL 44.97 ± 11.54 44.22 ± 10.49 0.386
a
LDL-C, mg/dL 118.28 ± 31.61 116.97 ± 33.34 0.606
a
BUN, mg/dL 16.58 ± 4.53 16.50 ± 4.28 0.835
a
Cr, mg/dL 1.08 ± 0.12 1.08 ± 0.12 0.811
a
AST, IU/L 30.32 ± 17.27 34.06 ± 30.40 0.067
a
ALT, IU/L 27.27 ± 14.89 29.36 ± 17.46 0.096
a
Data are expressed as mean ± standard deviation or number (%). 2 hr-insulin and 2 hr-glucose represent the insulin and glucose concentra-
tions 120 min after an oral glucose tolerance test. 
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; BMD, bone mineral density; HDL-C, high density lipoprotein cholesterol; 
LDL-C, low density lipoprotein cholesterol; ALT, alanine transaminase; AST, aspartate aminotransferase. 
aP values were calculated using an unpaired T-test, 
bP values were calculated by Pearson’s chi-square test.297
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normal group was -1.34 ± 1.42 while the BMD T-score of the 
prediabetic group was -1.33 ± 1.30; this difference was not sig-
nificant (P = 0.924). On chi-square testing following classifica-
tion of the BMD T-score according to WHO standards, no 
significant difference was found between the two groups (P = 
0.688, Table 1).
  Among the 272 prediabetic patients, excluding 9 patients 
who did not undergo the 75 g oral glucose tolerance test, a to-
tal of 263 patients were divided to the three groups: cases with 
IFG only, cases with IGT only, and cases with both IFG and 
IGT. The BMD T-score of each of these groups was compared 
with the normal group; no significant difference was observed 
(Table 2).
Relationship of blood glucose and insulin with BMD 
No significant difference in the BMD between the normal 
Table 2.  Subgroup analysis of BMD T-scores in prediabetics
Group
P value
Normal (n = 406) IFG only (n = 80) IGT only (n = 114) IFG and IGT (n = 69)
BMD T score  -1.34 ± 1.42 -1.37 ± 1.34 -1.44 ± 1.28 -1.19 ± 1.32
T score group 0.665
a
≥ -1.0 160 (40.2) 32 (40.0) 39 (34.2) 30 (43.5) 0.557
b
-1.0 >  ≥ -2.5 168 (42.2) 32 (40.0) 56 (49.1) 32 (46.4)
< -2.5 70 (17.6) 16 (20.0) 19 (16.7) 7 (10.1)
Data are expressed as mean ± standard deviation or number (%). 
BMD, bone mineral density; IFG, impaired fasting glucose; IGT, impaired glucose tolerance. 
aP values were calculated by one-way ANOVA, 
bP values were calculated by Pearson’s chi-square test.
Table 4.  BMD T-scores according to the fasting insulin levels in normal, prediabetic, and diabetic subjects
Fasting insulin level
P value < 25%
(≤ 5.2 mU/L )
25-50% 
(5.2 <  ≤ 6.6 mU/L)
50-75%
(6.6 <  ≤ 8.9 mU/L)
> 75% 
(> 8.9 mU/L )
BMD T score -1.53 ± 1.28 -1.48 ± 1.47 -1.16 ± 1.37 -1.16 ± 1.31 0.004
a
T score group < 0.001
b
≥ -1.0 63 (31.7) 68 (34.2) 88 (43.9) 95 (47.5)
-1.0 <  ≤ -2.5 97 (48.7) 92 (46.2) 86 (42.8) 77 (38.5)
< -2.5 39 (19.6) 39 (19.6) 27 (13.4) 28 (14.0)
Data are expressed as mean ± standard deviation or number (%). 2 hr-insulin represents the insulin concentrations at 120 min after an oral glu-
cose tolerance test. 
BMD, bone mineral density. 
aP values were calculated by one-way ANOVA, 
bP values were calculated by linear association analysis.
Table 3.  BMD T-scores in the normal, prediabetic, and diabetic subjects
Group
P value
Normal (n = 406) Prediabetes (n = 272) DM (n = 123)
BMD T score  -1.31 ± 1.42 -1.36 ± 1.30 -1.30 ± 1.34 0.870
a
T score group
≥ -1.0 160 (40.2) 106 (39.0) 48 (39.0) 0.558
b
-1.0 <  ≤ -2.5 168 (42.2) 126 (46.3) 57 (46.3)
< -2.5 70 (17.6) 40 (14.7) 18 (14.6)
Data are expressed as mean ± standard deviation or number (%).
BMD, bone mineral density; DM, diabetes mellitus. 
aP values were calculated by one-way ANOVA, 
bP values were calculated by linear association analysis.298
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group, the prediabetic group, and the diabetic group was ob-
served (Table 3). All subjects were divided into quartiles based 
on the fasting insulin and insulin levels 2 hours after a 75 g oral 
glucose load, and the BMD of each group was compared. As 
the concentration of fasting insulin increased, the mean BMD 
T-score also increased (P = 0.004). Additionally, on chi-square 
testing following classification of the BMD according to WHO 
standards, the subjects with high concentrations of fasting in-
sulin belonged to the groups with higher BMD T-scores (P < 
0.001, Table 4). When comparing these groups based on the 
insulin levels 2 hours after oral administration of 75 g glucose, 
no significant difference in the mean BMD T-score was found. 
Table 5.  BMD T-scores according to the 2 hr-insulin levels in normal, prediabetic, and diabetic subjects
2 hr-insulin level
P value < 25%
(≤ 12.1 mU/L)
25-50%
(12.1 <  ≤ 20.5 mU/L )
50-75%
(20.5 <  ≤ 35.4 mU/L )
> 75%
(> 35.4 mU/L )
BMD T score -1.39 ± 1.34 -1.46 ± 1.32 -1.33 ± 1.57 -1.17 ± 1.19 0.199
a
T score group 0.017
b
≥ -1.0 65 (35.1) 66 (35.1) 78 (41.1) 82 (43.6)
-1.0 <  ≤ -2.5 2.5 85 (45.9) 89 (47.3) 74 (38.9) 87 (46.3)
< -2.5 35 (18.9) 33 (17.6) 38 (20.0) 19 (10.1)
Data are expressed as mean ± standard deviation or number (%). 2 hr-insulin represents the insulin concentrations 120 min after an oral glu-
cose tolerance test. 
BMD, bone mineral density. 
aP values were calculated by one-way ANOVA, 
bP values were calculated by linear association analysis.
Table 6.  Univariate analysis of associations between the BMD T-score and clinical and laboratory parameters in the prediabetic 
subjects
Correlation coefficient Partial correlation coefficient
R P value R P value
Age, yr -0.124 0.041
Height, cm 0.014 0.818 0.003 0.963
Weight, kg 0.134 0.027 0.119 0.058
Waist circumference, cm -0.048 0.428 -0.068 0.227
BMI, kg/m
2 0.154 0.011 0.145 0.02
Fasting insulin, mU/L 0.027 0.663 0.020 0.748
Fasting blood glucose, mg/dL 0.061 0.319 0.053 0.402
2 hr-insulin, mU/L -0.002 0.979 -0.004 0.951
2 hr-glucose, mg/dL -0.033 0.595 -0.033 0.603
Percent body fat, % 0.191 0.002 0.193 0.002
Visecral fat, kg 0.166 0.006 0.170 0.006
Percent visceral fat, % 0.151 0.013 0.164 0.009
HbA1C, % 0.133 0.028 0.146 0.020
Total cholesterol, mg/dL 0.185 0.002 0.220 < 0.001
Triglyceride, mg/dL 0.017 0.780 -0.017 0.787
HDL-C, mg/dL 0.029 0.629 0.051 0.416
LDL-C, mg/dL 0.196 0.001 0.236 < 0.001
Data are given as Pearson’s correlation (R) coefficients with adjustment for age (r). 2 hr-insulin and 2 hr-glucose represent the insulin and glu-
cose concentrations 120 min after an oral glucose tolerance test. 
BMD, bone mineral density; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol. 
P < 0.01, P < 0.05.299
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Nonetheless, on chi-square testing performed after classifying 
the BMD T-score according to WHO standards, patients with 
higher insulin concentrations belonged to the group with high-
er T-scores (P = 0.017, Table 5). 
Correlation of BMD with clinical characteristics in the 
prediabetic group 
In the prediabetic group, the BMD demonstrated a statistically 
significant inverse correlation with age (r = -0.124, P = 0.041) 
and positive correlations with weight (r = 0.134, P = 0.027), BMI 
(r = 0.154, P = 0.011), percent body fat (r = 0.191, P = 0.002), 
percent visceral fat (r = 0.151, P = 0.013), total cholesterol (r = 
0.185, P = 0.002), and the LDL-C (r = 0.196, P = 0.001). Howev-
er, the correlation coefficients for these associations were be-
tween 0.1 and 0.3, and thus, the correlations were not very 
strong. No relationship was observed between the BMD and 
fasting insulin levels, fasting blood glucose, and the insulin 
and blood glucose levels 2 hours after oral administration of 
75 g of glucose. The BMD also demonstrated a positive corre-
lation with glycosylated hemoglobin; again, the correlation 
was not strong (r = 0.133, P = 0.028). Adjustment for age did 
not alter the results (Table 6). As age, BMI, glycosylated hemo-
globin, and LDL-C all demonstrated a correlation with BMD 
in the prediabetic group, a multiple regression analysis with 
these variables was performed. Only the LDL-C was found to 
be a significant variable (β = 0.007, P = 0.005) (Table 7). How-
ever, on a step-wise multiple regression model, age (β = -0.026, 
P < 0.001), BMI (β = 0.079, P < 0.001), and LDL-C (β = 0.004, 
P = 0.016) were found to be significant variables (Table 8).
DISCUSSION
It is well known that insulin plays a critical role in glucose me-
tabolism. Upon recognition that it also exerts anabolic effects 
on bone metabolism, diabetes has become a subject of interest 
in bone metabolism studies. The direct effect of insulin on bone 
metabolism has not yet been determined, but a high level of 
expression of insulin receptors on osteoblasts has been report-
ed [6]. It was observed that the binding of insulin to insulin 
receptors accelerated cell proliferation, collagen synthesis, 
production of alkaline phosphatase, and glucose intake [7-10]. 
In addition to the direct effects of insulin on osteoblasts, insu-
lin has been found to render osteoblasts more sensitive to IGF 
by the suppression of IGFBP-1; this induces a synergistic effect 
with the actions of parathyroid hormone and induces indirect 
synergistic effects with other substances that mediate anabolic 
effects on bone metabolism [11,12]. 
  The anabolic effects of insulin on bone metabolism can be 
confirmed in animals with experimentally induced diabetes. 
Maor et al. [13] observed that IGF-1, IGF-1 receptor, and in-
sulin receptor were reduced in the skeletal growth centers of 
diabetic rats. Insulin receptor transduces intracellular signals 
through insulin receptor substrate (IRS), and IRS-1 and IRS-2 
have been revealed to play an important role in bone turnover 
and bone formation, respectively [14]. With the observations 
that the insulin receptor was also detected in osteoclasts and 
that insulin suppresses osteoclast activity, the effects of insulin 
on reducing bone resorption could be predicted and studied 
[15]. Additionally, non-osmotic hypercalciuria was observed 
in diabetic rats, and has been reported to induce the effects of 
calcium deficiency [16]. It has also been reported that when hy-
Table 7.  Variables identified by multivariate linear regression 
analysis as being predictive of the BMD T-score in prediabetic 
subjects
Unstandardized 
coefficients P value R
2
β SD
0.075
Age, yr -0.020 0.011 0.071
BMI, kg/m
2 0.041 0.027 0.137
HbA1c, % 0.294 0.174 0.093
LDL-C, mg/dL 0.007 0.002 0.005
Data are expressed as standardized coefficients (β) using multivariate 
regression analysis.
BMD, bone mineral density; SD, standard deviation; BMI, body mass 
index; LDL-C, low density lipoprotein cholesterol. 
P < 0.01.
Table 8.  Variables identified by stepwise regression analysis as 
being predictive of the BMD T-score in prediabetic subjects
Unstandardized 
coefficients P value R
2
β SD
0.068
Age, yr -0.026 0.007 < 0.001
BMI, kg/m
2 0.079 0.018 < 0.001
LDL-C, mg/dL 0.004 0.002 0.016
Data are expressed as standardized coefficients (β) using multivariate 
regression analysis.
BMD, bone mineral density; SD, standard deviation; BMI, body mass 
index; LDL-C, low density lipoprotein cholesterol.
P < 0.01, P < 0.05.300
Lee JH, et al.
Korean Diabetes J 2010;34:294-302 www.e-kdj.org
perglycemia is persistent, advanced glycation end-products ac-
cumulate and result in the reduction of bone formation by os-
teoblasts and an increase in bone resorption by osteoclasts [17]. 
  Several studies focusing on changes in BMD and risks for 
bone fracture have been conducted in diabetic patients. Prior 
studies have found that BMD was decreased in type 1 diabetes 
though it was unchanged or increased in type 2 diabetes. In 
type 2 diabetes, adjustment for BMI did not alter these results. 
Insulin secretion is decreased in type 1 diabetes, but increased 
in type 2 diabetes. Therefore, the anabolic effects of insulin could 
be confirmed. However, in both type 1 and type 2 diabetes, the 
relative risk for hip fracture was increased by 6.3-6.9 times and 
1.4-1.7 times, respectively. In type 2 diabetes, the BMD was 
increased as did the risk for fracture. A possible explanation 
for this may be an increased number of falls due to deterioration 
of visual acuity or proprioception caused by diabetes [18].
  We conducted comparative studies on the changes in BMD 
in the normal and prediabetic groups using an ultrasono-
graphic bone densitometer. We noted no significant difference 
in BMD between these groups. The BMD demonstrated sig-
nificant correlations with age, BMI, percent of body fat, per-
cent visceral fat, and cholesterol. The subjects were divided 
into quartiles according to the concentration of insulin in the 
normal, prediabetic, and diabetic groups. The BMD T-scores 
were divided to three groups according to the WHO stan-
dards. Chi-square analysis was performed between the insulin 
groups and the BMD T-score groups. Interestingly, as the con-
centration of insulin increased, more patients were assigned to 
the groups with higher BMD T-scores. Therefore, it was con-
firmed that insulin exerts anabolic effects on bone metabo-
lism. However, there was no significant difference in BMD be-
tween the prediabetic and normal group. There have been 
conflicting reports in the previous studies of type 2 diabetic; in 
some studies, the BMD was reduced while in others it was in-
creased or unchanged [19]. This is thought to be secondary to 
numerous factors, other than insulin, affecting BMD [3]. Addi-
tionally, in a study that examined the differences in BMD be-
tween males and females with type 2 diabetes patients, the 
BMD was found to be increased in females, while the BMD of 
males was not significantly changed; this result is consistent 
with the current study which included only males [20].
  In the Rotterdam study, the BMD and risk of fracture were 
examined in 792 male and female diabetic patients older than 
55 years. They compared subjects with type 2 diabetes with the 
subjects without diabetes. Subset analyses were performed, di-
viding the subjects on the basis of the glucose tolerance test, 
into already treated diabetes, newly diagnosed diabetes, IGT, 
and normal glucose tolerance groups. Even after adjustment 
for age and gender, the femur neck BMD of the diabetic and 
IGT groups was significantly increased [21], yet in the IGT 
group, the change in the lumbar spine BMD was not statisti-
cally significant. Similarly, the change in femur BMD was not 
significant after adjustment for BMI, impairment of the lower 
extremities, smoking, and the use of diuretics, in addition to 
adjustments for age and gender. That study included both males 
and females and researchers used a dual energy X-ray absorp-
tiometry (DXA) for assessing the BMD. Strotmeyer et al. [22] 
examined BMD and fracture risk in 2,797 males and females 
between 70 and 79 years of age using DXA. These investigators 
found that in both males and females, the BMD of the hip joint 
was statistically increased in the IFG group. 
  Korean studies on the correlation of diabetes with osteopo-
rosis are rare. Kim et al. [23] examined the correlation of non-
insulin dependent diabetes with osteoporosis in 63 postmeno-
pausal women using DXA. These authors found that the lum-
bar spine and femur BMD of the diabetic group was signifi-
cantly higher than that of the normal group. Even after adjust-
ment for BMI and postmenopausal status, the BMD differenc-
es remained significant. Park et al. [24] measured the BMD of 
30 male and 30 female diabetic patients suspected as having 
diabetic foot disease as well 30 male and 30 female normal in-
dividuals using DXA. They found that the forefoot BMD of 
the diabetic group was significantly lower than that of the con-
trol group. Yet, in this study, the foot BMD of the patients sus-
pected as having diabetic foot disease was evaluated, and so 
the study may have limitations in assessing the association of 
diabetes with osteoporosis. 
  Although it is well known that age and weight are factors 
that mediate effects on BMD, there are no studies that have ana-
lyzed the factors mediating effects on BMD in prediabetics. In 
the current study, correlation analysis performed in the predi-
abetic group found that age, BMI, glycosylated hemoglobin, 
and LDL-C are factors that mediate effects on BMD. In a mul-
tiple regression analysis, only the LDL-C levels were found to 
be a significantly correlated factor. In a step-wise multiple re-
gression model, age and weight were found to be significantly 
associated factors with BMD. It is anticipated that if an in-
creased number of subjects are included in future studies, age 
may also be found to be a significant factor.
  Depending on the particular study, cholesterol has been re-301
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ported as having a positive, inverse, or no correlation with BMD 
[25-27]. It has recently been reported that 3-hydroxy-3-meth-
ylglutaryl (HMG)-CoA reductase inhibitors increase BMD 
and aid in fracture healing; this has been demonstrated to be 
independent of lipid reductions and rather due to enhancing 
the expression of osteoblasts through bone morphogenetic 
protein-2. Additionally, HMG-CoA reductase inhibitor sup-
presses osteoclast activity and may act as an anti-bone resorp-
tion agent [28]. As cholesterol increases, it may be a marker for 
relatively good nutrition and so may be a factor that increases 
the BMI. Hence, the effects of cholesterol on BMD need to be 
considered. The positive correlation of cholesterol with BMD 
observed in our study warrants further investigation. 
  The current study has several limitations. This is a cross-
sectional study. Ultrasonography was used to determine BMD 
instead of DXA. Additionally, bone turnover markers and an-
drogen concentrations were not measured. Finally, the major 
risk factors for male osteoporosis (drinking, smoking, and physi-
cal activity) were not analyzed.
  Our study is important as it is the first Korean study that has 
examined the changes in BMD in prediabetic patients. Further 
studies are required to elucidate the associations between the 
risk level of actual fracture and changes in BMD during the 
progression from a prediabetic state to frank diabetes. 
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